Company: SCLXW
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0000950170-25-108029
Chunk: 6

Company: Scilex Holding Co
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1A
Chunk 6
---
 model and generate revenues depends on a number of factors including our ability to: 

•successfully complete ongoing clinical trials and obtain regulatory approvals for our current and future product candidates; 

•identify new acquisition or in-licensing opportunities; 

•successfully identify new product candidates and advance those product candidates into pre-clinical studies and clinical trials; 

•raise additional funds when needed and on terms acceptable to us; 

•attract and retain experienced management and advisory teams; 

•add operational, financial and management information systems and personnel, including personnel to support clinical, manufacturing and planned future commercialization efforts and operations; 

•launch commercial sales of our product candidates, whether alone or in collaboration with others; 

•initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; 

•set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party payors; 

•achieve market acceptance of product candidates in the medical community and with third-party payors and consumers; and 

•maintain, expand and protect our intellectual property portfolio. 

If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable. 

Since our inception, we have incurred significant net losses, with net losses of $72.8 million and $114.3 million for the years ended December 31, 2024 and 2023, respectively. For the six months ended June 30, 2025 and 2024, we had